Medigene AG
XETRA:MDG1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
HP Inc
NYSE:HPQ
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (1.8), the stock would be worth €0.06 (58% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4.3 | €0.13 |
0%
|
| 3-Year Average | 1.8 | €0.06 |
-58%
|
| 5-Year Average | 0.9 | €0.03 |
-80%
|
| Industry Average | 182.4 | €5.7 |
+4 169%
|
| Country Average | 9 | €0.28 |
+111%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
€-12m
|
/ |
Jul 2024
€-2.8m
|
= |
|
|
€-12m
|
/ |
Dec 2024
€-12.5m
|
= |
|
|
€-12m
|
/ |
Dec 2025
€-12.2m
|
= |
|
|
€-12m
|
/ |
Dec 2026
€-11.1m
|
= |
|
|
€-12m
|
/ |
Dec 2027
€-10.5m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Medigene AG
XETRA:MDG1
|
440k EUR | 4.3 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 14 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 11.9 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 20.7 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 13.1 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 40.2 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 10.5 | 30.7 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 6.2 |
| Median | 9 |
| 70th Percentile | 13.6 |
| Max | 6 112.6 |
Other Multiples
Medigene AG
Glance View
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. The company is headquartered in Planegg, Bayern and currently employs 121 full-time employees. The company went IPO on 2000-06-30. The firm focuses on the development of personalized T cell-based immunotherapies. The company develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The firm operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.
